Adults: Depression: Depression of all types, including reactive and severe depression and depression accompanied by anxiety. Paroxetine is indicated for the prevention of relapse and also recurrence of further depressive episodes. In the treatment of depressive disorders, Paroxetine exhibits comparable efficacy to standard antidepressants. In general, improvement in patients starts after one week but does not become superior to placebo until the second week of therapy.
Paroxetine, in addition to its significant antidepressant effects, also improves associated symptoms of anxiety. There is also some evidence that Paroxetine may be of therapeutic value in patients who have failed to respond to standard therapy.
Morning dosing with Paroxetine does not have any detrimental effect on either the quality or duration of sleep. Moreover, patients are likely to experience improved sleep as they respond to Paroxetine therapy.
Where it is clinical practice to co-prescribe short-acting hypnotics with antidepressants, no additional adverse events have been recorded.
Paroxetine is effective in improving depression and suicidal ideation concurrently during the first few weeks of therapy.
Long term treatment with Paroxetine has shown that efficacy is maintained for periods of at least one year.
Obsessive Compulsive Disorder: Paroxetine is indicated for the treatment of Obsessive Compulsive Disorder (OCD).
In a placebo-controlled trial, the efficacy of Paroxetine in the treatment of OCD has been maintained for at least 1 year.
Panic Disorder: Paroxetine is indicated for the treatment of Panic Disorder with and without agoraphobia.
The combination of Paroxetine and cognitive-behavioural therapy has been shown to be significantly more effective than cognitive-behavioural therapy alone in the treatment of Panic Disorder.
In a placebo-controlled trial, the efficacy of Paroxetine in the treatment of Panic Disorder has been maintained for up to 1 year.
Social Anxiety Disorder/Social Phobia: Paroxetine has been shown to be effective in the treatment of Social Anxiety Disorder/Social Phobia.
Generalised Anxiety Disorder: Paroxetine has been shown to be effective in the treatment of Generalised Anxiety Disorder. In a placebo-controlled trial, the efficacy of Paroxetine in the treatment of Generalised Anxiety Disorder has been maintained for up to 32 weeks.
Post-traumatic Stress Disorder: Paroxetine has been shown to be effective in the treatment of Post-traumatic Stress Disorder.
All indications: Children and adolescents (<18 years).
Paroxetine is not indicated for use in children or adolescents aged <18 years.
Controlled clinical studies in children and adolescents with major depressive disorder failed to demonstrate efficacy, and do not support the use of Paroxetine in the treatment of depression in this population.
The safety and efficacy of Paroxetine in children aged <7 years has not been studied.